Project Grant R21AA033141
- The National Institute on Alcohol Abuse and Alcoholism awarded the Board of Regents of the University of Nebraska $368,551 on May 4, 2026, under the Alcohol Research Programs (CFDA 93.273) to support research on novel targeting mechanisms for alcohol-enhanced colorectal liver metastasis. The recipient, through its University of Nebraska Medical Center division in Omaha, Nebraska, will develop and optimize nanoparticle formulations to inhibit hepatic macrophage activation and hepatic stellate...
- The National Institute on Alcohol Abuse and Alcoholism awarded the Board of Regents of the University of Nebraska, acting through its University of Nebraska Medical Center division, $194,292 on June 11, 2026, under the Alcohol Research Programs (CFDA 93.273) to support a five-year research and career development project investigating epigenetic mechanisms in fetal alcohol spectrum disorder. The award funds a research program designed to identify ethanol-induced epigenetic alterations responsible...
- The National Institute on Alcohol Abuse and Alcoholism awarded the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center division, $402,938 on August 3, 2026, under the Alcohol Research Programs grant (CFDA 93.273). The award funds development of an automatic segmentation algorithm using deep learning to identify and measure the bed nucleus of the stria terminalis (BNST) in brain imaging data. The research applies this algorithm to the NCANDA dataset...
- The National Institute on Alcohol Abuse and Alcoholism awarded The University of Texas Health Science Center at San Antonio $664,792 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate post-transcriptional mechanisms and cellular senescence in age-related alcoholic liver disease. The research targets dysregulated nutrient sensing as a hallmark of aging that drives hepatic steatosis progression toward cirrhosis and hepatocellular carcinoma. The recipient will...
- The National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health within the Department of Health and Human Services, awarded $682,736 to Beth Israel Deaconess Medical Center, Inc. on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate myeloid-derived suppressor cells (MDSCs) in alcohol-associated steatohepatitis. The award funds research characterizing MDSC phenotypes and immunoregulatory capacity in alcohol-associated hepatitis...
- The National Institute on Alcohol Abuse and Alcoholism awarded Cedars-Sinai Medical Center $1.235 million under the Alcohol Research Programs (CFDA 93.273) on September 10, 2025, to investigate the role of prohibitin 1 (PHB1) in ethanol's sensitizing effect on colorectal liver metastasis. Research will examine how excessive alcohol intake depletes hepatocyte nuclear and cytosolic PHB1, increasing matrix metalloproteinase-7 (MMP-7) expression and rendering the liver susceptible to colorectal...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Medical University of South Carolina $488,077 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate molecular and functional adaptations in the nucleus reuniens, a midline thalamic region implicated in alcohol-related cognitive deficits. The research addresses how chronic alcohol exposure produces cognitive dysfunction that impairs treatment outcomes and increases relapse risk. The project will...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Administrators Of Tulane Educational Fund (doing business as Tulane University) $401,626 on September 26, 2025, under the Alcohol Research Programs (CFDA 93.273) to investigate plasma membrane rupture in alcohol-associated hepatitis. The recipient will determine the role of plasma membrane rupture (PMR) in alcohol-associated liver disease and investigate the mechanism by which cholestasis promotes hepatocellular PMR in that...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Regents of the University of California, San Francisco $613,750 on June 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate brain glucose metabolism dysfunction in alcohol use disorder. The research examines how alcohol activates the mTORC1 signaling pathway in dopamine D1 receptor-expressing neurons within the nucleus accumbens, leading to suppression of glycolytic enzymes including aldolase A and...
- The National Institute on Alcohol Abuse and Alcoholism, part of the Department of Health and Human Services National Institutes of Health, awarded $702,720 to Indiana University Indianapolis on August 10, 2026, under the Alcohol Research Programs (CFDA 93.273) project grant R01AA031671. The award funds research investigating posterior default mode network modulation as a treatment target in alcohol use disorder. The research examines how dysfunction in the medial posterior default mode...
The National Institute on Alcohol Abuse and Alcoholism awarded the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center division, $219,118 on August 1, 2026, under the Alcohol Research Programs (CFDA 93.273). The award funds research into the molecular mechanisms linking chronic alcohol consumption to prostate cancer progression and metastatic castration-resistant prostate cancer. The recipient will investigate alcohol-induced endoplasmic reticulum stress and Golgi disruption, specifically examining how ethanol activates ATF6 to suppress SEC12 transcription, impairing Golgi maintenance and triggering fragmentation. The work will assess alcohol-induced aberrant glycosylation of integrins and fibronectin through the enzyme MGAT5, and evaluate their clustering at the plasma membrane via galectin-3 interactions. Research will combine in vitro studies in prostate fibroblasts and in vivo mouse models bearing orthotopic tumors to define ATF6's role in alcohol-driven tumor progression and alternative glycosylation-dependent mechanisms beyond classical integrin-fibronectin RGD motif binding. Performance will occur in Omaha, Nebraska, with a period of performance from August 1, 2026, through July 31, 2028. This is an R21 exploratory/developmental grant, a non-renewable assistance type used to support novel, preliminary investigations under the NIAAA program to develop fundamental knowledge applicable to treatment and prevention of alcoholism and alcohol-related disorders.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $219.1k | 8/3/26 |